Impact of combination therapy and early de-escalation on outcome of ventilator-associated pneumonia caused by Pseudomonas aeruginosa

References

• Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165:867–903.
   PubMed Web of Science ®Google Scholar
• Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. Lancet. 2013;13:665–671.
   PubMed Web of Science ®Google Scholar
• Fujitani S, Sun H-Y, Yu VL, et al. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest. 2011;139:909–919.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society: Guidelines for the management of adults with hospital-acquired, ventilator associated, and health-care-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicentre study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007;35:1888–1895.
   PubMed Web of Science ®Google Scholar
• Heyland DK, Dodek P, Muscedere J, et al. Canadian Critical Care Trials Group. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med. 2008;36:737–744.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, De Pascale G, Trecarichi EM, et al. Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med. 2013;39:682–692.
   PubMed Web of Science ®Google Scholar
• Planquette B, Timsit JF, Misset BY, et al. Pseudomonas aeruginosa ventilator-associated Pneumonia. Predictive factors of treatment failure. Am J Respir Crit Care Med. 2013;188:69–76.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Orega A, et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med. 2014;40:32–40.
   PubMed Web of Science ®Google Scholar
• Gonzalez L, Cravoisy A, Barraud D, et al. Factors influencing the implementation of antibiotic de-escalation and impact of this strategy in critically ill patients. Crit Care. 2013;17:R140.
   PubMed Web of Science ®Google Scholar
• Rello J, Mariscal D, March F, et al. Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection? Am J Respir Crit Care Med. 1998;157:912–916.
   PubMed Web of Science ®Google Scholar
• Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122:262–268.
   PubMed Web of Science ®Google Scholar
• McCabe WR, Jackson CG. Gram-negative bacteremia: etiology and ecology. Arch Intern Med. 1962;110:847–855.
   Google Scholar
• Bone RC, Fischer CJ, Clemmer TP, et al. Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med. 1989;17:389–393.
   PubMed Web of Science ®Google Scholar
• Brown DF, Wooton M, Howe RA. Antimicrobial susceptibility testing breakpoints and methods from BSAC to EUCAST. J Antimicrob Chemother. 2016;71:3–5.
   PubMed Web of Science ®Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281.
   PubMed Web of Science ®Google Scholar
• Peña C, Gómez-Zorrilla S, Oriol I, et al. Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-associated pneumonia outcome: predictors of early and crude mortality. Eur J Clin Microbiol Infect Dis. 2013;32:413–420.
   PubMed Web of Science ®Google Scholar
• Crouch Brewer S, Wunderink RG, Jones CB, et al. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest. 1996;109:1019–1029.
   PubMed Web of Science ®Google Scholar
• Venier AG, Gruson D, Lavigne T, et al. Identifying new risk factors for Pseudomonas aeruginosa pneumonia in intensive care units: experience of the French national surveillance, REA-RAISIN. J Hosp Infect. 2011;79:44–48.
   PubMed Web of Science ®Google Scholar
• Parker CM, Kutsogiannis J, Muscedere J, et al. Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care. 2008;23:18–26.
   PubMed Web of Science ®Google Scholar
• Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998;157:531–539.
   PubMed Web of Science ®Google Scholar
• Surveillance des infections nosocomiales en réanimation adulte. Réseau REA-Raisin, Institut de Veille Sanitaire; 2012. [Internet]. [cited 1 Feb 2016]. Available from: http://www.invs.sante.fr/Publications-et-outils/Rapports-et-syntheses/Maladies-infectieuses/2013/Surveillance-des-infections-nosocomiales-en-reanimation-adulte2.
   Google Scholar
• Jung B, Sebbane M, Chanques G, et al. Previous endotracheal aspirate allows guiding the initial treatment of ventilator-associated pneumonia. Intensive Care Med. 2009;35:101–107.
   PubMed Web of Science ®Google Scholar
• Lopez-Ferraz C, Ramírez P, Gordon M, et al. Impact of microbial ecology on accuracy of surveillance cultures to predict multidrug resistant microorganisms causing ventilator-associated pneumonia. J Infect. 2014;69:333–340.
   PubMed Web of Science ®Google Scholar
• Alvarez-Lerma F, Alvarez B, Luque P, etet al. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care. 2006;10:R78.
   PubMed Web of Science ®Google Scholar
• Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med. 2004;32:2183–2190.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest. 2006;129:1210–1218.
   PubMed Web of Science ®Google Scholar
• Joung MK, Lee JA, Moon SY, et al. Impact of de-escalation therapy on clinical outcomes for intensive care unit-acquired pneumonia. Crit Care. 2011;15:R79.
   PubMed Web of Science ®Google Scholar
• Chaudhary M, Shrivastava SM, Varughese L, et al. Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients. Curr Clin Pharmacol. 2008;3:118–122.
   PubMedGoogle Scholar
• Nseir S, Deplanque X, Di Pompeo C, et al. Risk factors for relapse of ventilator-associated pneumonia related to nonfermenting Gram negative bacilli: a case-control study. J Infect. 2008;56:319–325.
   PubMed Web of Science ®Google Scholar